Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 57 Stomach Neoplasms 45 Carcinoma, Non-Small-Cell Lung 36 Colorectal Neoplasms 24 Esophageal Squamous Cell Carcinoma 19 Rectal Neoplasms 11 Lung Neoplasms 11 Esophageal Neoplasms 11 Nasopharyngeal Carcinoma 10 Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 7 Pancreatic Neoplasms 7 Neoplasm Metastasis 7 Cholangiocarcinoma 6 Uterine Cervical Neoplasms 5 Small Cell Lung Carcinoma 5 Triple Negative Breast Neoplasms 4 Recurrence 4 Liver Neoplasms 4 Endometrial Neoplasms 4 Colonic Neoplasms 4 Carcinoma, Renal Cell 4 Solid Tumor 3 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma, Extranodal NK-T-Cell 3 Colorectal Cancer Metastatic 3 Carcinoma 3 Breast Neoplasms 3 Advanced Solid Tumors 3 Advanced Solid Tumor 3

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumour × sintilimab × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡